ALKS
E597289
ALKS is the stock ticker symbol for Alkermes plc, a biopharmaceutical company focused on developing medicines for central nervous system diseases and oncology.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Alkermes plc | 0 |
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
stock ticker symbol ⓘ |
| country | Ireland NERFINISHED ⓘ |
| currencyOfStock | USD ⓘ |
| develops |
CNS therapeutics
ⓘ
oncology therapeutics ⓘ |
| engagesIn |
drug commercialization
ⓘ
drug development ⓘ drug discovery ⓘ |
| focusesOn |
central nervous system diseases
ⓘ
oncology ⓘ |
| foundedBy | Michael Wall NERFINISHED ⓘ |
| foundingDate | 1987 ⓘ |
| hasADR | American depositary shares traded on NASDAQ as ALKS ⓘ |
| hasCUSIP | G01767105 ⓘ |
| hasEmployeeRange | 1000-5000 employees ⓘ |
| hasISIN | IE00B56GVS15 ⓘ |
| hasOffice | Waltham, Massachusetts, United States NERFINISHED ⓘ |
| hasPipeline |
CNS drug candidates
ⓘ
oncology drug candidates ⓘ |
| headquartersLocation | Dublin, Ireland NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| legalForm | public limited company ⓘ |
| listedOn | Nasdaq Stock Market NERFINISHED ⓘ |
| marketRegion |
Europe
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| notableProduct |
Aristada
NERFINISHED
ⓘ
Lybalvi NERFINISHED ⓘ Vivitrol NERFINISHED ⓘ |
| regulatoryFiling | SEC registrant in the United States ⓘ |
| represents | Alkermes plc NERFINISHED ⓘ |
| researchFocus |
immuno-oncology
ⓘ
neuroscience ⓘ |
| stockTicker | ALKS NERFINISHED ⓘ |
| therapeuticArea |
alcohol dependence
ⓘ
bipolar I disorder ⓘ cancer ⓘ major depressive disorder ⓘ opioid dependence ⓘ schizophrenia ⓘ |
| tradedAs | NASDAQ:ALKS NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.